+ All Categories
Home > Documents > Make or Buy’ Decisions in the Production

Make or Buy’ Decisions in the Production

Date post: 03-Jun-2018
Category:
Upload: cosimo-accoto
View: 222 times
Download: 0 times
Share this document with a friend

of 12

Transcript
  • 8/12/2019 Make or Buy Decisions in the Production

    1/12

    Make or buy decisions in the productionof health care goods and services: newinsights from institutional economics andorganizational theoryAlexander S. Preker,1 April Harding,2 & Phyllida Travis3

    A central theme of recent health care reforms has been a redefinition of the roles of the state and private providers.With a view to helping governments to arrive at more rational make or buy decisions on health care goods andservices, we propose a conceptual framework in which a combination of institutional economics and organizationaltheory is used to examine the core production activities in thehealth sector. Empirical evidence from actual productionmodalities is also taken into consideration. We conclude that most inputs for the health sector, with the exception ofhuman resources and knowledge, can be efficiently produced by and bought from the private sector. In the healthservices of low-income countries most dispersed production forms, e.g. ambulatory care, are already provided by theprivate sector (non-profit and for-profit). These valuable resources are often ignored by the public sector. Theproblemsof measurability and contestability associated with expensive, complex and concentrated production forms such ashospital care require a stronger regulatory environment and skilled contracting mechanisms before governments canrely on obtaining these services from theprivate sector. Subsidiary activities within theproduction process can often beunbundled and outsourced.

    Keywords:delivery of health care, methods; public sector; private sector; outcome and process assessment, healthcare; decision-making, methods; models, economic; models, organizational.

    Voir page 788 le resume en francais. En la pagina 788 figura un resumen en espanol.

    Public and private roles in thehealth sector

    Economic theory and empirical evidence provideample justification for significant engagement by thestate (1) in tackling problems of both equity (26) andefficiency (79) in the health sector. However,experience during the past two decades has revealeda range of problems in public production (10, 11)

    which have para llels with well- known marketimperfections in the private sector (1215). Theseproblems relate, among other things, to public

    accountability (16), informational asymmetry (17),abuse of monopoly power and failure of strategicpolicy formulation, and there are clear parallels inmarket failure (18).

    There is an urgent need to reform inefficientand bloated bureaucracies (1922) by exposingpublic services to competitive market forces (23),reducing the size of the public sector (24, 25) and

    increasing private sector participation (2629). Abetter match is desirable between the roles of thestate and the private sector and their respectivecapabilities (30). In most countries this meansrebalancing what is already a complex mix of publicand private roles in the health sector (31).

    Using a framework based on recent develop-ments in institutional economics and organizationaltheory, we argue for greater private participation in thegeneration of inputs and the provision of healthservices (32, 33). We also stress the importance of astrong stewardship function of governments in secur-

    ing equity, efficiency and quality objectives throughmore effective policy-making and financing (34).

    Theoretical underpinnings fora contracting framework

    The current tendency is to use at least one of threeapproaches in order to deal with public sector failurein thegeneration of inputs andthe provisionof healthservices. These approaches, indicated below indescending order of strength, involve:. exit possibilities (market forces through consumer

    choice);. voice (client participation);. loyalty (hierarchical sense of responsibility) (35).

    1 Lead Economist, World Bank, 1818 H. Street NW, Washington,DC 20433,USA (email: [email protected]). Requests for reprintsshould be addressed to this author.2 Institutional Economist, World Bank, 1818 H. Street NW,

    Washington, DC 20433, USA.3 Public Health Specialist, World Health Organization,1211 Geneva 27, Switzerland.

    Ref. No.00-0606

    779Bulletin of the World Health Organization, 2000, 78 (6) #World Health Organization 2000

  • 8/12/2019 Make or Buy Decisions in the Production

    2/12

    Exit should be used unless the weaker variants haveto be employed because the goods and servicesinvolved are not marketable. Exit options can beimplemented in parallel with other public sectormanagement reforms that increase voice and loyalty.

    From neoclassical economics...One of the central tenets of neoclassical economics isthat competitive forces in an optimally functioningmarket lead to a moreefficient allocation of resourcesthan command economy or non-market solutions.Neoclassical economic theory shows that, if certainconditions are met, competition produces an equili-brium in which it is impossible to make someonebetter off without making someone else worse off.

    The neoclassical model categorizes goods andservices as private, mixed or public. Private goodsexhibit excludability (consumption by one individualprevents consumption by another; there are no

    positive or negative externalities), rivalry (there iscompetition among goods based on price), andrejectability (individuals can choose to forgo con-sumption). True public goods have significantelements of non-excludability, non-rivalry, and non-rejectability. Mixed goods have some but not all ofthe characteristics of private goods (Fig. 1).

    According to neoclassical theory a breakdownoccurs in both efficiency and equity when publicgoods or services with significant externalities areallocated through competitive markets. Even publicgoods can be sold in private markets but usually thisleads to suboptimal quantity, quality or price, thereby

    creating a strong justification for collective action.Likewise, significant problems occur in efficiencyandequity when private goods are produced or providedby a public sector monopoly (23).

    The perfectly competitive Walrasian modelassumes that:. the goods involved behave like true private goods

    (i.e. there is excludability, rivalry and rejectability);

    . rights can be perfectly delineated;

    . there are no transaction costs.

    Applying this to the health sector reveals that mosthealth care goods and services have some degree of

    excludability, rivalry and rejectability. However,

    rights are often difficult to delineate, leaving multipleresidual claimants.Furthermore, transactioncosts areoften high. Even many health activities that generatesignificant externalities, such as sanitation services,the control and prevention of communicablediseases, health promotion, research and professionaleducation, are not pure public goods. For example, a

    vaccine given to one patient cannot simultaneouslybe consumed by another patient. Patients can choosenot to be vaccinated, and vaccination programmesmay compete for market share.

    Unfortunately, consumption characteristicsalone hardly ever indicate anything about the specific

    production processes that ensure technical effi-ciency. Although the neoclassical framework pro-vides a robust test to justify the need for stewardshipand financing, it does not help us understand theoptimal organizational arrangements for serviceproduction, being essentially institution-free (36). Itdoes not help to answer the following criticalquestion facing policy-makers. When a decision hasbeen taken to finance certain items, should the publicsector make or buy them?

    ... to institutional economics andorganizational theory

    Much progress has been made in identifying the keyfactors causing wide variations in the performancesof organizations. The developments most relevant tounderstanding the advantages and disadvantages ofdifferent arrangements for service delivery derivefrom principal/agent theory, transaction cost eco-nomics, property rights and public choice theory.

    These fields, often categorized as institutionaleconomics, deal with considerations of information,motivation and innovation and the implications forthe best possible organization of productive activity.Institutional economics is directly concerned with

    creating the best possible structures for organizations

    that consist of individuals pursuing multiple andoften conflicting interests (37).

    Agency theory. This framework shows thatsocial and political objectives may be more readilyachieved through a series of explicit and transparentcontracts for labour and services between an agent anda principal. The agent undertakes to perform varioustasks for the principal, in exchange for a mutuallyagreed award. The principal usually needs the effortsand expertise of the agent but has limited ability tomonitor the agents actions or evaluate whether theoutcome is satisfactory. On such matters as paymentand monitoring arrangements, the agency literature

    surveys the range of contracts observed in theeconomy with respect to incentives and cooperationamong self-interested but interdependent individuals

    Fig. 1.The nature of goods based on neoclassical economics

    Special Theme Health Systems

    780 Bulletin of the World Health Organization, 2000,78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    3/12

    (38). Several studies have generalized the agencyinsight from the employment context to the full rangeof relationships that make up the firm, nowconceptualized as a nexus of many contracts (39,40). The need for incentive alignment is pervasive in

    the health sector: the relationships between patient

    and physician or governments and contractingagencies are classical examples of the principal/agentstructure.

    Transaction cost economics. Transaction costeconomics emphasizes the limitations of contractsand the need for flexible means of coordinatingactivities. Principals and agents are both opportunis-tic. Agents seek to minimize aggregate productionand transaction costs and to maximize their benefits.Unless closely monitored, agents may be unreliable,engaging in behaviour such as rent-seeking, cheating,breech of contract and incomplete disclosure.Principals may try to maximize their benefits to such

    an extent that therelationship could become unviablefor the agent. The degree of such opportunism variesconsiderably from country to country and from onecultural setting to another. In some settings, such asmonopolistic national health services, opportunismmay be less apparent than in other settings whereproviders are more in the habit of competing witheach other. Opportunism may appear to be relativelypronounced in some countries, e.g. Chile, India, andthe USA. In others, e.g. Costa Rica, NewZealand, theScandinavian countries, Sri Lanka, and the UnitedKingdom, there is good evidence that principal/agent relationships within the national health services

    are vulnerable to opportunistic behaviour.This theory sheds most light on firm bound-aries and the conditions under which it is better toarrange activities within a hierarchy rather thaninteracting in a market with suppliers or othercontractors. More generally, vertically integrated

    organizations, simple spot contracts, franchises orjoint ventures are interpreted as discrete structuralalternatives, each offering different advantages anddisadvantages for effective governance (41). Gov-ernance arrangements are evaluated by comparingthe patterns of costs generated for planning, adaptingand monitoring production and exchange (42,43).

    Unlike public organizations, private firms havethe flexibility, indeed the requirement, to adjust theirgovernance structure to changes in the marketenvironment. This makes them fruitful sources ofbetter practices for governance arrangements. Public

    agencies that have tried adjusting public organiza-tions to changes in the market environment haveoften encountered problems with underlying incen-tive structures and their sustainability. This hashappened in relation to the formation of NationalHealth Service Trusts in the United Kingdom, theestablishment of the Hospitals Authority in HongKong, and the corporatization of publicly owned

    hospitals in New Zealand. Major policy reversals inNew Zealand and the United Kingdom have added

    weight to the argument that it would have been better

    to privatize than to settle for the imperfect middleground of public sector corporatization.

    Thus, for example, vertically integrated organi-zation, i.e. within a firm, arises as a response toproblems with market contracting. The firm sub-

    stitutes low-powered incentives, like salaried employ-

    ment, forthe high-poweredmarket incentives of profitand loss. Vertical integration, i.e. unified ownership,permits details of future relations between suppliers(including employees), producers and distributors toremain unspecified; differences can be adjudicated asevents unfold. It pools the risks and rewards of variousactivities undertaken by the organization, and canfacilitate the sharing of information, the pursuit ofinnovation, and a culture of cooperation.

    Notwithstanding these positive features, ver-tical integration suffers from characteristic weak-nesses as a mechanism of governance. The two mostprominent are the weakening of incentives for

    productivity and the proliferation of influenceactivities (see Box 1). Weak incentives arise whenpeople obtain shrinking gains from their own effortsas rewards and losses are spread throughout anorganization. From the standpointof transaction costeconomics, vertical integration is seen as thegovernance mechanism of last resort, even thoughthe focus is on the contracting problems thatmotivate internal organization. Even in the manyinstances where policy objectives imply that spotmarket transactions are undesirable, unified owner-ship arrangements are outperformed by contractualnetworks, virtual integration, franchising or conces-

    sioning.Property rights theory. Property rights theor-ists have attempted to find out why private owner-ship appears to have strong positive incentives forefficiency. Explanations have focused on the posses-sion of residual decision rights and the allocation of

    residual returns (45). Residual rights of control are therights to make any decisions regarding an assets usenotexplicitly contracted by lawor assigned to anotherby contract. Theowner of an asset usually holds these

    Box 1.Influence activities

    An important issue related to moral hazard and the structure oforganizations is that of influence activities and the associated

    costs, known as influence costs (44). Recent analysis has shed

    much light on the propensity of publicly owned service delivery

    organizations to capture inordinate portions of the sector

    budget, as well as their ability to influence sector policy to their

    benefit, often against the public interest.

    In the health sector, provider organizations try to gain

    advantages by affecting decisions on the distribution of

    resources or other benefits among providers. Such influence

    activities occur in all organizations, but countervailing forces are

    particularly weak in public service delivery structures. Influence

    costs are one of the most important costs of centralized control.

    Evidence of such activities in the health sector is seen in thetendency to allocate resources to tertiary and curative care at the

    expense of primary, preventive and public health activities.

    Production of health care goods and services

    781Bulletin of the World Health Organization, 2000, 78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    4/12

    rights, although the owner or the law may allocatemany rights to others. The notion of ownership asresidual control is relatively clear for a simple assetlike a motor car. It gets much more complicated

    when applied to an organization such as a firm. Large

    organizations bundle together many assets, and it

    may be unclear who has specific decision rights. Inaddition to residual decision rights, owners hold therights to residual revenue flows from their assets. Inother words, owners have the right to whateverrevenue remains after all funds have been collected,and all debts, expenses and other contractualobligations have been met.

    Political choice theory. This field focuses onthe self-interested behaviour of politicians, interestgroups and bureaucrats, and studies the implicationsfor effective government andthe size of government.Individuals are viewed as rational utility maximizers.Bureaucrats, attempting to maximize their budgets,

    acquire an increasing share of national income. As aresult the state grows well beyond what is needed forthe delivery of its core functions. Powerful interestgroups capture increasing portions of resources.Institutional rigidities develop which reduce eco-nomic growth (46).

    This analysis has led public choice theorists tosupport conservative political agendas which mini-mize the role of the state.

    Towards a new understanding ofthe production characteristics of goodsand services

    The principles of institutional economics lead to amuch more refined and useful understanding of thedifferent kinds institutional arrangements requiredfor the efficient and effective production of goodsand services. A model can be developed on the basisof two characteristics of goods, namely contestabilityand measurability (Box 2) (47).

    The contestability and measurabilitymatrix

    It is possible categorize all health care goods and

    services on a matrix along a continuum ranging fromhigh contestability and high measurability to lowcontestability, low measurability and significantinformational asymmetry. The following discussionrefers mainly to curative services and public healthservices, although the analysis could be extended tosome of the broader intersectoral determinants ofgood health, such as water, sanitation, education,healthy life-style policies and good nutrition.

    Production characteristics of inputs(factor markets)

    The contestability and measurability matrix for theproduction of inputs would be as indicated in Fig. 2.The production of consumable items and the

    retailing of drugs, medical supplies and other

    consumables would be the best example of highlycontestable goods where outputs are also easy tomeasure (Type I). There are usually many companiesjostling for a share of the market and few barriers toentry. The initial investment capital is modest and

    there are few requirements for specialized licensing or

    skills. Unskilled labour also belongs in this category.As we move across the first row in Fig. 2 anumber of factors begin contributing to increasingbarriers to entry, thereby reducing the contestabilityof the goods or services in question (Type II).Investment cost (sunk cost) and increasing technicalspecifications create moderate barriers to entry in themanufacturing of specialized equipment and sup-plies. The wholesaling of drugs, medical supplies andmedical equipment encounterssome barriers to entrybecause of larger investment requirements and morelimited supply and distribution chains. The speciali-zation and licensing of pharmacists contribute to

    these entry barriers. In the case of small capital stock,such as clinics and diagnostic centres, entry barriersare mainly created though certification and licensing.

    On moving across to Type III activities, e.g. theproduction of pharmaceuticals and high-technologymedical equipment, barriers to entry are much greaterbecause of large initial investment costs that cannot berecovered later when assets are sold (sunk costs).

    These production activities are also associated withcostly and long lead times needed for research,development and the registration of new products.

    Box 2.Contestability and measurability

    A market can be said to be perfectly contestable if firms can

    enter it freely (without any resistance from other firms) and

    subsequently leave it without losing any investments, while

    having equal access to technology (no asset specificity)

    (4851). Contestability allows competition for the market

    to substitute for competition in the market.

    Contestable goods are characterized by low barriers to entry

    andexit fromthe market, whereas non-contestable goods have

    high barriers such as "sunk cost", monopoly market power,

    geographical advantages and asset specificity. Investments in

    specific assets represent a sunk cost since their value cannot be

    recovered elsewhere (52). Two specific assets that are of

    particular importance in the health sector are expertise andreputation. Once incumbents have invested in activities that

    result in expertise or generate trust, they enjoy a significant

    barrier to entry for other potential suppliers, thereby lowering

    the degree of contestability. Opportunism, on the other hand,

    lowers such trust or barriers to entry. The degree of such

    opportunism varies from one country to another and between

    different cultural settings.

    Measurability in the health sector, as in other sectors, is the

    precision with which inputs, processes, outputs and outcomes

    of particular goods or services can be measured. It is difficult to

    measure with precision the output and outcome of health

    services, which are characterized by informational asymmetry

    the highly variable extent to which information about theperformance of a given activity is available to users,

    beneficiaries or contracting purchasing agencies.

    Special Theme Health Systems

    782 Bulletin of the World Health Organization, 2000,78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    5/12

    Other barriers to entry in this category include productdifferentiation (specialized medical equipment) andcopyright protection (drugs with brand names).Furthermore, the benefits arising from economies ofscope and scale have resulted in a significant global

    concentration of pharmaceutical and high-technology

    industries, giving them considerable monopoly power.For all the activities in the first row (Type I to Type III)the measurability of outputs remains high and there islittle informational asymmetry.

    On descending to the second row themeasurement of outputs and outcomes becomesmore problematic, although it is possible. Variousbarriers to entry reduce contestability. Training isalmost always associated with special licensing andlong lead times (Type V). The specialized labourmarket is usually associated with many professionalbarriers and consequent restrictions in the scope ofpractice and labour mobility. Contestability is even

    lower in Type VI. Most research and other knowl-edge-generating activities belong in this category, asdoes the training of specialized staff in universitiesand other higher education centres.

    There are no good examples of inputs for thehealth sector that would fit in the last row withsignificant informational asymmetry in addition tomeasurement problems.

    Production characteristics of outputs(product markets)It is also possible to categorize interventions andservices along a similar continuum ranging from high

    contestability and high measurability to low contest-ability, low measurability and significant informationasymmetry (Fig. 3). Whereas reduced contestabilityattributable to market concentration is one of themain problems encountered in factor markets(production of inputs), a key problem with interven-tions and other outputs (product markets) has to do

    with difficulties in specifying and measuring outputsand outcomes.

    The measurement of outputs and outcomesbecomes more problematic for Type IV, Type V and

    Type VI. Although routine diagnostic procedures,

    e.g. laboratory tests, may be highly contestable (there

    being many players in a competitive market with fewbarriers to entry), monitoring their performance interms of effectiveness and quality of the activitiesundertaken is much harder (Type IV). The same istrue for various non-clinical hospital activities.

    In Type V, contestability is reduced by variousbarriers to entry. Diagnostics involving high technol-ogy usually requires specialization, licensing and largesunk costs, giving existing players a marked advantageover new entrants. A further barrier to entry for theseactivities would be government policies controlling orrestricting the introduction of some new technologies(computerized tomography or nuclear magnetic

    resonance scanners). The outsourcing of clinicalinterventions usually involves the use of certifiedproviders. In all of these cases the measurement of

    outputs and outcomes is possible but more difficultthan in the case of activities in the first row.

    In addition to difficulties in measuring outputand outcomes, most clinical interventions are con-strained by informational asymmetry. Informationmay be readily apparent to patients, e.g. concerningthe quality of hospital services with respect toprivacy, the courtesy of clinical staff, the length of

    waiting periods, the cleanliness of bed sheets, thetaste of food, and other matters. However, in theabsence of survey techniques such information maynot be readily available to contracting policy-makersor administrative staff.

    For these reasons, ambulatory clinical carewould fall in Type VII with relatively low barriers toentry other than professional qualifications/certifica-tion of staff, but with high informational asymmetryand difficulties in the measurement of outputs andoutcomes. On moving across the third row, con-testability diminishes due to specialization andcost, in addition to measurement problems. Conse-

    quently, public health interventions, intersectoralaction programmes and inpatient clinical care are

    Type VIII activities.

    Fig. 2.Production characteristics of inputs (factor markets)

    Fig. 3.Production characteristics of outputs (product markets)

    Production of health care goods and services

    783Bulletin of the World Health Organization, 2000, 78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    6/12

    This leaves a few distinct activities such aspolicy-making, monitoring and evaluation in the

    Type IX category. The contestability and measur-ability of these activities are extremely low, and theyare therefore usually retained as a core part of an

    integrated bureaucracy.

    Make or buy decision grid

    PrioritizeIn many countries, make or buy decisions are madebefore policy-makers and providers have gonethrough a process of explicit prioritization aboutthe range of interventions to be financed throughpublic resources (including preventive services) andof ensuring that public subsidies are appropriatelytargeted (e.g. on the poor and other vulnerablegroups) (53). Countries often make hasty make orbuy decisions before prioritizing interventions thatare needed and affordable. Such prioritization iscomplicated by the fact that the costs of treatingdifferent illnesses vary greatly and often bear littlerelation to the effectiveness of available interventions(54). Furthermore, there may be a range of activitiesfor which information disclosure and coordinationthrough a strong stewardship function is sufficient.

    Decide who can produce whatOn the above basis it becomeseasyto map the goodsand services that can be bought or for whichcoordination is adequate, and those that are better

    produced in house by the public sector itself (Fig. 4).The size of the make in-house production triangledepends largely on the effectiveness of policyinstruments for dealing with problems of contest-ability and measurability.

    Decide whom to buy from and howOnce make or buy options have been settled it isnecessary to decide:. whom to buy from;. how to structure purchases.

    Whom to buy from. All possible producers should be considered

    (public, nongovernmental and private-for-profit;domestic and international).

    . Purchasing decisions should be based on con-

    siderations of the best products at the lowest

    prices responsive to specific needs: type of goods,price, quantity, after-acquisition support, time-liness, and so on (international competitivebidding should be considered if possible).

    . If there is no market, consideration should begiven to stimulating demand rather than in-houseproduction.

    . If contestability is low and there is no competitivemarket, consideration should be given to usingbenchmark purchasing based on estimated re-ference costs over which suppliers have tocompete for the market rather than in it.

    . If there is a dysfunctional market, consideration

    should be given to improving its function throughappropriate strategic subsidies or anti-trust regu-lations.

    How to buyThe contractual arrangement most suitable for agiven purchase should be chosen: spot market forunpredictable items, medium-term supply contractfor predictable items, franchise arrangements forstandardized needs at multiple locations, and rela-tional contracts for purchases that are difficult tomonitor (55).

    If a decision has been taken to buy, it is

    important that all potential producers are treated in thesame way. Among other things this means ensuringthat there are no hidden competitive advantages suchas tax concessions, access to subsidized capital, orprivileged access to information.

    Policy levers for enhancing makeor buy decisions

    Clearly, most goods and services havesome degree ofmarket imperfection in terms of reduced contest-ability and measurability. Governments have various

    instruments that can be used to deal with thissituation. In order of increasing intrusiveness, someof them are:

    requiring information disclosure; introducing regulations; contracting for services; providing subsidies or direct financing; public production.

    Standard instruments of governmentsFactor markets. For some inputs the production ofconsumables, unskilled labour, and the retailing ofdrugs, medical equipment and consumables there

    are few serious market imperfections such as reducedcontestability and low measurability (upper leftcorner of the matrix in Fig. 5). With minimal

    Fig. 4.Make or buy decision grid

    Special Theme Health Systems

    784 Bulletin of the World Health Organization, 2000,78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    7/12

    government intervention, e.g. requiring good infor-mation disclosure and some quality or safetystandards, competitive markets are best at producingthese inputs, the public production of which usuallyleads to low quality, lack of innovation, and

    inefficient production modalities.

    At the other extreme, the training of veryspecialized labour and the generation of knowledgeabout rare health conditions and their treatment ischaracterized by considerable market imperfectionsbecause of low contestability and reduced measur-ability. A mix of strong regulation and in-houseproduction is often needed to ensure adequategeneration of these inputs.

    Most other inputs can be bought. Markets,however, often give wrong signals about the level (i.e.surpluses and shortages), mix and distribution ofthese inputs. This is especially true in the case ofhuman resources and the production of pharmaceu-

    ticals and medical equipment where the training ordevelopment phase is very long. The skilled use ofregulations and contracting mechanisms is thereforeneeded when purchasing such inputs with moderatecontestability and measurability problems.

    Large producers may try to bring about a severereduction in contestability by erecting strong barriersto entry through collusion, protective policies (patentsand licensing requirements), benchmarking (manu-facturing standards), requirements for large sunkcosts, and a high degree of specialization (researchand development). For these inputs, stronger policymeasures may be needed, such as monopsony

    purchasing power and long-term contracts.Despite this complex landscape of character-istics of goods, governments could, in many areas ofreduced contestability and measurability, achievemost equity, efficiency and quality objectives throughregulations and contracting (54, 56).

    Product markets. As in the case of inputs,interventions and other outputs can be contractedout, i.e. purchased, and do not in principle have to beproduced in house.

    Decisions about which interventions to makein house and which to contract out are complicatedby the following factors..

    For some outputs, such as clinical interventions, itis much harder to specify what is to be deliveredthan is the case with inputs, and this makes itdifficult to manage the resulting contracts andprevent opportunistic behaviour among provi-

    ders. Such behaviour is particularly likely in thefield of private health insurance.

    . Contestability is often reduced for the samereasons as indicated above for inputs.

    . Complex health problems often require strategiccoordination among different interventions andother outputs (e.g. integrated care, continuity ofcare, appropriate and timely referrals).

    In the case of outputs, policy-makers have toexamine two additional questions before arriving atmake or buy decisions.

    Is there a need for a strategic coordinated

    response? To what degree do the goods and services benefit

    from continuing innovation and adaptability?

    For example, non-clinical activities such as custodialservices, catering, laundry and management do notrequire special strategic coordination. They canusually be unbundled and contracted out as standardservices to specialist firms without too muchcustomization. In contrast, clinical and public healthinterventions often have to be coordinated andadapted to the individuals and populations receivingthem and the organizations providing them. Experi-

    ence has shown that unbundling these activities oftenleads to problems, such as cost shifting, discontinuity

    of care and poor quality (57, 58).

    Policy levers that are often forgottenThe contestability and measurability of goods andservices are not static: they are influenced byelements of the systemic environment. Governmentpolicies directly affect this environment and thenature of goods and services, yielding alternativelevers to take them closer to or further away from theability to use the indirect tools of contracting andregulation. These levers include:. governance, i.e. the relationship between owners

    (governments) and health care organizations;. the market environment, i.e. competition in or for

    markets in goods and services;. purchasing mechanisms, i.e. funding or payment

    arrangements for goods or services.

    These factors exert a powerful influence on thenature of goods and services, and hence on the abilityto ensure delivery through indirect mechanisms.

    Governance and internal incentive regime

    Changes made in the relationship between govern-ment and organizations, i.e. governance, influencethe characteristics of the health care goods and

    Fig. 5.Policies to deal with reduced contestability and measurability

    Production of health care goods and services

    785Bulletin of the World Health Organization, 2000, 78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    8/12

    services in question. This relationship can bemodified substantially in five dimensions:

    the rights given to managers to make decisions; the residual claimant status; the degree of market exposure;

    accountability arrangements;

    the adequa cy of subsidies to cov er socialfunctions (59).

    Contestability may be enhanced by: unbundling large bureaucratic structures (modi-

    fication in governance); outsourcing other functions to specialized provi-

    ders (modification in payment system); exposing all public and private actors to the same

    potential benefits and losses attributable to marketexposure (modification in governance and pay-ment system);

    decreasing barriers to entry caused by political

    interference or unwarranted trust in publicproduction (modification in market structure); explicitly separating contestable commercial func-

    tions and non-commercial social objectives (modi-fication in governance and stewardship).

    Measurability may be enhanced by: relying on quantifiable results (output or outcome

    measures) for accountability and performancetargets rather than process (inputs and bureau-cratic procedures) (modification in governanceand payment system);

    shifting from difficult-to-define long-term rela-

    tionships (employment or service arrangements)to shorter-term, more specific contractual ar-rangements (modification in payment system);

    using quantifiable monetary incentives rather thannon-monetary incentives, e.g. involving consid-erations of ethics, ethos and status, which are

    more difficult to track (modification in paymentsystem);

    tightening reporting, monitoring and account-ability mechanisms (modification in governanceand payment system).

    For example, by removing restrictive government

    monopolies from vaccination services (governance/market), programmes could be shifted into a Type IIor even a Type I position. It is easy to measure thenumber of children vaccinated or contracting a givendisease, and to have moderately low barriers to entry

    for firmsthat want to provide such services on behalfof government. Similar action applied to otherservices could shift many of them from the lowerright corner of the grid towards the upper left corner(Fig. 6).

    Likewise, through better information on out-come and policies favouring clearly defined con-tracts, performance benchmarks, and a tightening of

    reporting, monitoring and accountability mechan-isms, it would be possible to shift tertiary andquaternary care provided in universities from a lowcontestability/measurability position to a medium

    position. The same would be true for public healthservices and public health activities that are often partof the responsibility of ambulatory care providers,e.g. vaccination.

    Several factors may also alter the goods

    characteristics of pharmaceuticals, medical equip-

    ment and consumable supplies. Medical equipmentor drugs that were highly specialized and veryexpensive due to development costs, patent protec-tion, and a small market share (Type III goods) onlyten years ago, may now behave as ordinary goods(Type I or Type II). Examples include the productionof generic drugs by many companies once patentprotection expires or the rapid increase in the use ofsigmoidoscopes and/or transcutaneous surgical in-struments once the technology is no longer new andprices have dropped.

    Changes in the characteristics of goods do notoccur in only one direction. The properties of goods

    may become less contestable and more difficult tomeasure. Organizational reforms do not always leadto increased decision rights, residual claimant status,market exposure, accountability arrangements andexplicit subsidies to cover social functions. Manynational health systems that were introduced thoughthe nationalization of ownership and productionduring the past 50 years deliberately shifted goodsand services in the opposite direction.

    Market imperfections may increase rather thanreduce barriers to entry. Doctors, dentists andpharmacists collude to restrict entry by potentialcompetitors. Hospitals have a natural monopoly for

    their services for patients livingnearby, andcan createmonopoly power through relations with otherhospitals and referring doctors. Local medicalequipment distributors that represent some of thebiggest international companies can easily mono-polize domestic markets. Pharmaceutical retailers can

    control mark-ups through professional cartels. Thepublic and nongovernmental sectors have a compe-titive advantage over the private sector because oftheir access to subsidized or free capital fromdomestic and foreign donors.

    Market environment

    One of the central arguments in favour of exposingproviders to market forces is that, in a functioningmarket, competitive forces lead to a more efficientallocation of resources than is the case withcommand economy or non-market solutions. Thestructure of the market to which organizations areexposed, therefore, has a critical influence on theirbehaviour. It may directly determine the strategies tobe adopted for the generation of increased revenue.

    Policies that influence the competitive envi-ronment through regulations or contracting cansignificantly alter the contestability of health caregoods and services. Likewise, informational asym-

    metry can be reduced by policies that increase theavailability of good information on health services,enhance the institutional capacity of health care

    Special Theme Health Systems

    786 Bulletin of the World Health Organization, 2000,78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    9/12

    providers to deal with such information, andimprovepatients understanding of health problems.

    Such policies not only address some of theunderlying contestability and measurability problemsbut also shift both the contestability/measurability

    grid and the boundaries of needed government

    intervention to ensure favourable outcomes (Fig. 7).Conversely, in a less competitive environmentwith weak pol icies and data for overco min ginformational asymmetry the grid for services thatfall into the left upper corner (Types I, II and IV) maycontract while the grid in the right lower corner(Types VI, VIII and IX) expands.

    Purchasing mechanismsProvider payment systems influence the properties ofgoods by interacting with three of the key elements ofthe internal incentive regime of health care organiza-tions: distribution of residual claims, market expo-

    sure and provisions for social functions. Serviceproviders in particular respond differently to alter-native funding and payment mechanisms. Forexample, collective purchasing by a strategic socialhealth insurance fund in Germany sends signals toproviders which differ from those associated withregulated competition in the USA, consumer-drivendemand through out-of-pocket payments in India,medical savings accounts in Singapore, and monop-sonistic purchasing in the United Kingdom.

    While reforms in governance may endow a givenorganization with formal claims to residual revenue indifferent categories, the structure of the payments

    system directly determines whether the claims haveany real meaning or incentive effect. If, for example,services must be delivered at prices below cost there

    will be no residual revenue to claim. Thus therelationship of costs to the price-setting and capital-charging formula in the payments system is a criticaldeterminant of theincentives of themodel. Thecrucialfactor is whether marginal cost-saving efforts byproviders can generate revenue flows that they cankeep without deterioration in quality or effectiveness.

    When reforms to organizations such as hospitalsentail a shift to earning revenue through the delivery ofservices in a market, thenatureof the emerging market

    becomes crucial. Often the government is the largestor only buyer. In this case the process and terms under

    which the government purchaser engages providersmay well determine the degree of pressure to whichthey are subjected for delivery.

    In order to gain maximum benefits fromreforms that expose the public sector to competition

    with the private sector, adequate steps should betaken to secure competitive neutrality. This requires:. moneterization of social functions, e.g. explicit

    subsidies that adequately cover costs plus areasonable margin in the delivery of services tonon-paying or non-insured patients;

    . standardization of the fee structure and cost ofcapital for both the public sector and the privatesector.

    Conclusions

    Many low-income countries have large inefficientpublic sectors producing goods and services thatcould be bought from nongovernmental providers.However, moving from one system to another is not

    easy. It takes time and must be accompanied bycapacity-building in areas such as contracting,regulation and the coordination of nongovernmentalproviders.

    A three-step process can be used so as to movegradually from one balance to another in the publicprivate mix in service delivery. If there is already alarge private sector thepublic sector shouldrecognizeits existence and slowly increase the use of itsresources through better coordination and contractsand the establishment of a positive regulatoryenvironment. Once experience has been gained incoordinating and contracting with providers, the

    lessons learnt can be transferred to other priorityareas where there may be no activity by nongovern-mental providers. Finally, where the public sector is

    Fig. 6.The nature of health care goods based on organizational economics

    Fig. 7.Shifting the contestability/measurability grid and neededpublic policies

    Production of health care goods and services

    787Bulletin of the World Health Organization, 2000, 78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    10/12

    clearly engaged in inefficient activities, as is the casewith the production of many inputs, they can beconverted through outright privatization and subse-quently bought from the private sector (56).

    However, the public sector may not be

    involved in areas of strategic importance, such as

    the collective financing of health services. Conse-

    quently, in parallel with moving out of the area ofproduction of goods and services, in many low-income and middle-income countries it may bedesirable to have a more integrated approach andgreater public sector involvement in health care

    financing, knowledge generation and the provision of

    human resources. n

    Resume

    Decisions relatives a la sous-traitance des produits et services de sante : nouveauxenseignements de leconomie institutionnelle et de la theorie de lorganisationLes systemes de sante ont quatre fonctions centrales :generer des apports (connaissances, ressources humai-nes, produits pharmaceutiques, materiel et produitsmedicaux) ; assurer un financement (mobilisation desressources, mise en commun des risques et servicesdachat) ; fournir des services (sante publique, soinsambulatoires et soins hospitaliers) ; et soccuper deladministration generale (elaboration des politiques,supervision, coordination, reglementation, surveillanceet evaluation). Les systemes de sante de bon nombre depays a revenu faible ou moyen ne fonctionnent pas bien,parfois a cause du developpement inegal de cesfonctions et parfois a cause de desequilibres entre lerole joue par lEtat et celui joue par le marche.

    Le present article propose un cadre conceptuelvisant a aider les gouvernements a parvenir a desdecisions plus rationnelles en matiere de sous-traitancepource qui est de la production de produits et de servicesde sante. Par exemple, concernant les travaux nonqualifies et la vente au detail de medicaments, defournitures et de produits medicaux, les rendements sontfaciles a mesurer et les fournisseurs sont en generalnombreux. Dans la plupart des pays, ces activites sontlaissees au secteur prive et lengagement de lEtat y estminimal. Une participation plus importante de lEtat estsouvent necessaire sous la forme de reglementations etde sous-traitance strategique visant a assurer desresultats optimaux pour ce qui est de la fabrication demateriel et de fournitures et de la vente en gros desmedicaments, des fournitures et du materiel medicaux.La production de substances pharmaceutiques et demateriel medical complexe est associee a un investisse-ment initial important et a une concentration du marche,qui limitent la concurrence. Cependant, meme dans cecas, la reglementation en matiere de qualite, les mesuresantitrust et les achats en situation de monopole sontpreferables a une production publique qui, en general, sesolde par la fabrication de produits de mauvaise qualite,une absence dinnovation, une technologie depassee etdes modalites de production inefficaces.

    Tandis que la reduction de la concurrenceimputable a la concentration du marche est lun desprincipaux problemes rencontres dans la productiondapports dans ce domaine, le probleme essentiel auquelse heurte loffre des services de sante publique et desservices curatifs nest pas sans rapport avec les difficultesqui se posent pour preciser et observer les produits et lesresultats obtenus. Dans beaucoup de pays, les soinsambulatoires sont deja assures par le secteur prive (a butlucratif ou non) par le biais dun financement public(sous-traitance) ou par paiement direct dans le secteurinformel. Les soins hospitaliers et les services de santepublique exigent des mecanismes de sous-traitance pluselabores et un environnement reglementaire plus solideavant que les pouvoirs publics puissent les confier ausecteur prive. Toutefois, meme en pareilles circonstan-ces, des activites auxiliaires telles que les services degestion et de soutien non clinique peuvent souvent etredissociees et externalisees.

    Lassurance-maladie presente un tableau diffe-rent. Si beaucoup de fournisseurs et de produitsobservables (couverture de lassurance) plaident enfaveur de solutions obeissant aux lois du marche,lassurance medicale privee est, dans la pratique,associee a une grave carence du marche et a une pertede protection financiere generale de la population contrele cout de la maladie. Pour des raisons strategiques, laplupart des pays choisissent de conserver cette fonctiondans le secteur public.

    Tout milite en faveur dune plus grande participa-tion du secteur prive aux apports et a la fourniture desservices de sante parallelement a lengagement plusimportant des pouvoirs publics en faveur des objectifsdequite, defficacite et de qualite, lie au mandatdadministration generale et de financement qui est leleur. Malheureusement, bon nombre de pays a revenufaible et moyen consacrent une grande partie des fondspublics a la production, laissant peu de ressources pourlachat strategique de services aupres dorganisationsnon gouvernementales et de dispensateurs prives.

    Resumen

    Decisiones relativas a la subcontratacion de productos y servicios de salud:nuevas ensenanzas de la economa institucional y la teora de la organizacionLos sistemas de salud tienen cuatro funciones basicas:generacion de insumos (conocimientos, recursos huma-nos, productos farmaceuticos, equipo medico y material

    fungible); financiacion (movilizacion de recursos, man-comunacion de riesgos y compra de servicios); prestacionde servicios (salud publica, atencion ambulatoria y

    Special Theme Health Systems

    788 Bulletin of the World Health Organization, 2000,78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    11/12

    atencion hospitalaria); y rectora (elaboracion depolticas, supervision, coordinacion, reglamentacion,vigilancia y evaluacion). Los sistemas de salud demuchos pases de ingresos bajos y medios no funcionanadecuadamente, a veces a causa del desarrollodesparejo de esas funciones y a veces de los

    desequilibrios entre la funcion del Estado y la delmercado.En el presente artculo se propone un marco

    conceptual para ayudar a los gobiernos a adoptardecisiones mas racionales por lo que respecta a lasubcontrata durante la produccion de bienes y serviciosde atencion de salud.Por ejemplo, en lo concernientea laproduccion de personal no calificado y la venta al pormenor de medicamentos, suministros medicos y otrosbienes fungibles, los resultados son faciles de medir y porlo general hay muchos proveedores. En muchos pases,estas actividades se dejan en manos del sector privado yla participacion del Estado es mnima. A menudo, es

    necesaria una mayor participacion del Estado en formade reglamentaciones y contratos estrategicos para lograrresultados optimos en la fabricacion de equipo ysuministros y en la venta al por mayor de medicamentos,suministros y equipo medicos. La produccion depreparaciones farmaceuticas y equipo medico complejorequiere una inversion inicial y una concentracion delmercado considerables, y esos dos factores limitan lacompetencia. Incluso en este caso, sin embargo, lareglamentacion de la calidad, las medidas antimonopolioy la compra en regimen de monopsonio son preferibles ala produccion publica, que por lo general implicaproductos de baja calidad, falta de innovacion,

    tecnologa obsoleta y modos de produccion ineficaces.Mientras que la reduccion de la competenciaatribuible a la concentracion del mercado es uno de losproblemas principales con que se tropieza en laproduccion de insumos, el problema fundamental en la

    produccion de servicios de salud publica y servicioscurativos tiene que ver con las dificultades que planteanla especificacion y la observacion de los productos y losresultados. En muchos pases, la atencion ambulatoria yala presta el sector privado (con o sin fines de lucro)mediante financiacion publica sobre una base con-

    tractual o mediante financiacion directa en el sectorinformal. La atencion hospitalaria y los servicios de saludpublica requieren mecanismos mas cualificados decontratacion y un entorno normativo mas estricto paraquelos gobiernospuedan adquirir esos servicios al sectorprivado. Aun en estas circunstancias, las actividadessubsidiarias, como la gestion y los servicios de apoyo noclnicos, a menudo se pueden disociar y confiar aterceros.

    Ahora bien, el panorama es diferente en lo tocanteal seguro de enfermedad. Aunque son numerosos losproveedores y los resultados observables (coberturamediante seguro) que hacen preferibles las soluciones

    basadas en el mercado, el seguro de enfermedadprivado, en la practica, esta asociado a fallos graves delmercado y a una perdida de la proteccion financierageneral de la poblacion contra los gastos de enfermedad.Por razones estrategicas, la mayora de los pasesprefieren mantener esta funcion dentro del sectorpublico.

    Hay solidos argumentos en favor de una mayorparticipacion del sector privado en la generacion deinsumos y la prestacion de servicios de salud, que seacompane paralelamente de un mayor empeno delgobierno en conseguir los objetivos de equidad,eficiencia y calidad mediante la funcion de rectora y la

    financiacion. Lamentablemente, muchos pases deingresos bajos y medios dedican una gran parte de losfondos publicos a la produccion, dejando pocos recursospara la compra estrategica de servicios a organizacionesno gubernamentales y proveedores privados.

    References

    1. Arrow K.Arrows theorem: the paradox of social choice.

    New Haven, CT, Yale University Press, 1980.

    2. Evans RG.Strained mercy.Toronto, Butterworth, 1984.

    3. Rice T.The economics of health reconsidered. Chicago, IL,

    Health Administration Press, 1998.

    4. Bator, F.The anatomy of market failure.Quarterly Journalof Economics, 1958,72: (3): 351379.

    5. Atkinson AB, Stiglitz JE.Lectures on public economics.

    Maidenhead, McGraw-Hill, 1980.

    6. Musgrave RA, Musgrave PB.Public finance in theory

    and practice.4th edition. New York, McGraw-Hill, 1984.

    7. Barer ML et al, eds.Health, health care and health

    economics: perspectives on distribution.Chichester, John Wiley

    & Sons, 1998.

    8. van Doorslaer E, Wagstaff A, Rutten F, eds.Equity in

    the finance and delivery of health care: an international

    perspective.Oxford, Oxford Medical Publications, 1993.

    9. Arrow KW.Uncertainty and the welfare economics of medical

    care.American Economics Review, 1963,53(5): 940973.

    10. Barr N, ed.Labor markets and social policy in central and

    Eastern Europe.New York,Oxford University Press for TheWorld Bank, 1994.

    11. Investing in people and growth. In:World development report

    1996: from plan to market.New York, Oxford University Press

    for The World Bank, 1996: 123132.

    12. Wolf CJ.A theory of non-market failure.Journal of Law

    and Economics, 1979,22(1): 107139.

    13. Peacock A.On the anatomy of collective failure.Public Finance,1980,35(1): 3343.

    14. Weimer DL, Vining AR.Policy analysis: concept and practice.

    Englewood Cliffs, NJ, Prentice Hill, 1989.

    15. Vining AR, Weimer DL.Government supply and government

    production failure: a framework based on contestability. Journal

    of Public Policy, 1990,10(1): 122.

    16. Moore M.Creating public value.Cambridge, MA, Harvard

    University Press, 1995.

    17. Fama EF, Jensen MC.Agency problems and residual claims.

    Journal of Law and Economics, 1983,26 (2): 327349.

    18. Preker AS, Harding A, Girishankar N.The economics

    of private participation in health care: new insights from

    institutional economics.Geneva, International Labour

    Organization, 2000.

    19. World Bank.World development report 1993: investingin health.New York, Oxford University Press for The World Bank,

    1993.

    Production of health care goods and services

    789Bulletin of the World Health Organization, 2000, 78 (6)

  • 8/12/2019 Make or Buy Decisions in the Production

    12/12


Recommended